Loading financials from SEC filings…
Drug manufacturers · Healthcare · Fiscal year ends Dec 31
IDEAYA Biosciences reported revenue of $219M in the fiscal year ended Dec 2025, up 3024.4% from the year before. Operating income was −$159M, an operating margin of −72.8%, and net income was −$114M. Operating cash flow of −$71M less capital expenditure of $2M left free cash flow of −$73M.
Ranks among the 78 drug manufacturers companies we cover (1st = best; for debt, the least indebted). Green = top third, red = bottom third.
Last 5 fiscal years
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 27.9 | 50.9 | 23.4 | 7.0 | 219 |
| Research & development | 58.2 | 89.5 | 130 | 295 | 315 |
| Operating income | −50.3 | −62.5 | −134 | −327 | −159 |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income | −49.8 | −58.7 | −113 | −274 | −114 |
| Diluted EPS | −1.41 | −1.42 | −1.96 | −3.36 | −1.28 |
| Diluted shares | 35.3 | 41.4 | 57.5 | 81.7 | 88.5 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | 92.0 | 68.6 | 157 | 84.4 | 113 |
| Receivables | 1.1 | 0.2 | 0.0 | 0.0 | – |
| Current assets | 251 | 370 | 533 | 690 | 667 |
| Net PP&E | 4.8 | 6.5 | 6.2 | 9.0 | 8.2 |
| Total assets | 381 | 388 | 649 | 1,124 | 1,109 |
| Payables | 2.1 | 4.3 | 6.6 | 15.4 | 17.6 |
| Deferred revenue | 29.0 | 8.6 | 0.0 | – | – |
| Current liabilities | 45.2 | 31.7 | 27.1 | 46.1 | 58.8 |
| Total liabilities | 79.8 | 38.5 | 28.2 | 64.9 | 86.4 |
| Shareholders' equity | 302 | 349 | 621 | 1,059 | 1,023 |
| Backlog (remaining obligations) | 64.2 | 13.7 | – | – | 162 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | −55.8 | −87.2 | −115 | −248 | −71.1 |
| Capital expenditure | 2.6 | 3.4 | 2.4 | 3.9 | 2.4 |
| Free cash flow | −58.4 | −90.6 | −118 | −251 | −73.5 |
| Depreciation & amortisation | 1.7 | 2.1 | 2.5 | 2.4 | 2.7 |
| Stock-based compensation | 8.2 | 11.6 | 18.5 | 34.7 | 46.1 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | 82.3% | −54.1% | −70.1% | 3024.4% |
| Operating margin | −179.9% | −122.7% | −574.9% | −4671.1% | −72.8% |
| Net margin | −178.1% | −115.2% | −483.0% | −3921.1% | −52.0% |
| Return on equityBlank when equity is negative | −16.5% | −16.8% | −18.2% | −25.9% | −11.1% |
| ROCEEBIT ÷ (assets − current liabilities) | −15.0% | −17.5% | −21.6% | −30.3% | −15.2% |
| Free cash flow margin | −209.1% | −177.9% | −502.9% | −3592.0% | −33.6% |
| Cash conversion (CFO ÷ net income) | 1.12x | 1.49x | 1.02x | 0.90x | 0.63x |
| Receivable days | 14 | 2 | 0 | 0 | – |
| Current ratio | 5.56x | 11.7x | 19.7x | 15.0x | 11.3x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.